May 2007
Volume 48, Issue 13
Free
ARVO Annual Meeting Abstract  |   May 2007
Varying Doses of Intravitreal Bevacizumab (Avastin) for the Treatment of Proliferative Diabetic Retinopathy
Author Affiliations & Notes
  • P. Stergiou
    Department of Ophthalmology, Ippokration General Hospital, Thessaloniki, Greece
  • D. Kokkinou
    Department of Ophthalmology, Ippokration General Hospital, Thessaloniki, Greece
  • K. Malamos
    Department of Ophthalmology, Ippokration General Hospital, Thessaloniki, Greece
  • A. Felekidis
    Department of Ophthalmology, Ippokration General Hospital, Thessaloniki, Greece
  • S. Kailari
    Department of Ophthalmology, Ippokration General Hospital, Thessaloniki, Greece
  • Footnotes
    Commercial Relationships P. Stergiou, None; D. Kokkinou, None; K. Malamos, None; A. Felekidis, None; S. Kailari, None.
  • Footnotes
    Support None.
Investigative Ophthalmology & Visual Science May 2007, Vol.48, 1395. doi:https://doi.org/
  • Views
  • Share
  • Tools
    • Alerts
      ×
      This feature is available to authenticated users only.
      Sign In or Create an Account ×
    • Get Citation

      P. Stergiou, D. Kokkinou, K. Malamos, A. Felekidis, S. Kailari; Varying Doses of Intravitreal Bevacizumab (Avastin) for the Treatment of Proliferative Diabetic Retinopathy. Invest. Ophthalmol. Vis. Sci. 2007;48(13):1395. doi: https://doi.org/.

      Download citation file:


      © ARVO (1962-2015); The Authors (2016-present)

      ×
  • Supplements
Abstract

Purpose:: To test the varying doses of intravitreal bevacizumab in patients with retinal neovascularization (NVE or NVD) secondary to diabetes mellitus in a interventional, consecutive, retrospective case series. The study was conducted in compliance with the Declaration of Helsinki.

Methods:: Twenty eyes of 19 patients with retinal neovascularization due to Proliferative Diabetic Retinopathy. Patients were divided in four groups received intravitreal bevacizumab (150 µg -1.25 mg). First group received 1.25 mg, second group 600 µg, third group 300 µg and fourth group 150 µg in a single intravitreal injection under sterile conditions. Ophthalmic evaluations included non-standardized Snellen visual acuity (VA), complete ophthalmic examination, optical coherence tomography and mostly fluorescein angiography to identify the presence of NVE or NVD and the amount of leakage.

Results:: No significant ocular or systemic adverse effects were noted. Complete resolution of angiographic leakage of neovascularization was noted in all eyes from the first week.

Conclusions:: Short-term results suggest that intravitreal bevacizumab even in lower doses than standard is effective in reversing temporarily NVE or NVD in diabetics.

Keywords: diabetic retinopathy • neovascularization 
×
×

This PDF is available to Subscribers Only

Sign in or purchase a subscription to access this content. ×

You must be signed into an individual account to use this feature.

×